Loading data for LPCN — first visit, this takes a few seconds.
Lipocine Inc. (LPCN)
NasdaqCM: LPCN
· Real-Time Price · USD
2.09
+0.00 (0.00%)
At close: Aug 25, 2026, 8:00 PM
2.15
+0.00%
After-hours: 4:10 PM
The price, the headline numbers and the latest news, in one place.
Lipocine Inc. (LPCN) Stock Price, Analysis & Data
0.00% (1D)
No data available
| Bid | 1.51 |
| Market Cap | 17.73M |
| Revenue (ttm) | 1.57M |
| Net Income (ttm) | -11.85M |
| 0.46 | |
| -1.85 | |
| n/a | |
| -1.73 | |
| P/B (ttm) | 0.81 |
| P/S (ttm) | 11.29 |
| Earnings Date | Aug 14, 2025 |
| Ask | 2.67 |
| Volume | 17,778 |
| Avg. Volume (20D) | 66,217 |
| Open | 2.11 |
| Previous Close | 2.09 |
| Day's Range | 2.06 - 2.11 |
| 52-Week Range | 1.81 - 12.37 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LPCN
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone lau...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 22, 2013
Employees 14
Stock Exchange NasdaqCM
Ticker Symbol LPCN
Website https://www.lipocine.com
Financial Performance
In 2025, Lipocine's revenue was 1.98M, a decrease of -82.35% compared to the previous year's 11.2M. Earnings were -9.63M, a decrease of -115,371.85%.
Financial StatementsEarnings Surprise
Lipocine has released their quarterly earnings on Aug 4, 2026:
- Revenue of $190.1K misses estimates by $0, with -69.48% YoY decline.
- EPS of -0.32 exceeds estimates by 0.08, with 21.95% YoY growth.
Lipocine Inc. is scheduled to release its earnings on Aug 14, 2025, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2